409 related articles for article (PubMed ID: 32950749)
1. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study.
Kim D; Adeniji N; Latt N; Kumar S; Bloom PP; Aby ES; Perumalswami P; Roytman M; Li M; Vogel AS; Catana AM; Wegermann K; Carr RM; Aloman C; Chen VL; Rabiee A; Sadowski B; Nguyen V; Dunn W; Chavin KD; Zhou K; Lizaola-Mayo B; Moghe A; Debes J; Lee TH; Branch AD; Viveiros K; Chan W; Chascsa DM; Kwo P; Dhanasekaran R
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1469-1479.e19. PubMed ID: 32950749
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study.
Satapathy SK; Roth NC; Kvasnovsky C; Hirsch JS; Trindade AJ; Molmenti E; Barish M; Hirschwerk D; Da BL; Bernstein D;
Hepatol Int; 2021 Jun; 15(3):766-779. PubMed ID: 33826042
[TBL] [Abstract][Full Text] [Related]
3. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
Marjot T; Moon AM; Cook JA; Abd-Elsalam S; Aloman C; Armstrong MJ; Pose E; Brenner EJ; Cargill T; Catana MA; Dhanasekaran R; Eshraghian A; García-Juárez I; Gill US; Jones PD; Kennedy J; Marshall A; Matthews C; Mells G; Mercer C; Perumalswami PV; Avitabile E; Qi X; Su F; Ufere NN; Wong YJ; Zheng MH; Barnes E; Barritt AS; Webb GJ
J Hepatol; 2021 Mar; 74(3):567-577. PubMed ID: 33035628
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study.
Ge J; Pletcher MJ; Lai JC;
Gastroenterology; 2021 Nov; 161(5):1487-1501.e5. PubMed ID: 34284037
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.
Moon AM; Singal AG; Tapper EB
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2650-2666. PubMed ID: 31401364
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
7. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
8. Disparity in liver cancer incidence and chronic liver disease mortality by nativity in Hispanics: The Multiethnic Cohort.
Setiawan VW; Wei PC; Hernandez BY; Lu SC; Monroe KR; Le Marchand L; Yuan JM
Cancer; 2016 May; 122(9):1444-52. PubMed ID: 26916271
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.
van Meer S; van Erpecum KJ; Sprengers D; Coenraad MJ; Klümpen HJ; Jansen PL; IJzermans JN; Verheij J; van Nieuwkerk CM; Siersema PD; de Man RA
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):352-9. PubMed ID: 26629867
[TBL] [Abstract][Full Text] [Related]
10. Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response.
Le AK; Zhao C; Hoang JK; Tran SA; Chang CY; Jin M; Nguyen NH; Yasukawa LA; Zhang JQ; Weber SC; Garcia G; Nguyen MH
Aliment Pharmacol Ther; 2017 Sep; 46(6):605-616. PubMed ID: 28766727
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
Mallet V; Beeker N; Bouam S; Sogni P; Pol S;
J Hepatol; 2021 Oct; 75(4):848-855. PubMed ID: 33992699
[TBL] [Abstract][Full Text] [Related]
12. Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder.
Chiu WC; Shan JC; Yang YH; Chen VC; Chen PC
Drug Alcohol Depend; 2021 Nov; 228():109096. PubMed ID: 34600254
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).
Sarin SK; Choudhury A; Lau GK; Zheng MH; Ji D; Abd-Elsalam S; Hwang J; Qi X; Cua IH; Suh JI; Park JG; Putcharoen O; Kaewdech A; Piratvisuth T; Treeprasertsuk S; Park S; Wejnaruemarn S; Payawal DA; Baatarkhuu O; Ahn SH; Yeo CD; Alonzo UR; Chinbayar T; Loho IM; Yokosuka O; Jafri W; Tan S; Soo LI; Tanwandee T; Gani R; Anand L; Esmail ES; Khalaf M; Alam S; Lin CY; Chuang WL; Soin AS; Garg HK; Kalista K; Batsukh B; Purnomo HD; Dara VP; Rathi P; Al Mahtab M; Shukla A; Sharma MK; Omata M;
Hepatol Int; 2020 Sep; 14(5):690-700. PubMed ID: 32623632
[TBL] [Abstract][Full Text] [Related]
14. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.
Kim D; Cholankeril G; Li AA; Kim W; Tighe SP; Hameed B; Kwo PY; Harrison SA; Younossi ZM; Ahmed A
Liver Int; 2019 Sep; 39(9):1661-1671. PubMed ID: 31081997
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection.
Ioannou GN; Bryson CL; Weiss NS; Miller R; Scott JD; Boyko EJ
Hepatology; 2013 Jan; 57(1):249-57. PubMed ID: 22532055
[TBL] [Abstract][Full Text] [Related]
16. Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes.
Vutien P; Kim NJ; Moon AM; Pearson M; Su F; Berry K; Gelman H; Ioannou GN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1717-1727. PubMed ID: 32951216
[TBL] [Abstract][Full Text] [Related]
17. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.
N'Kontchou G; Paries J; Htar MT; Ganne-Carrie N; Costentin L; Grando-Lemaire V; Trinchet JC; Beaugrand M
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1062-8. PubMed ID: 16844421
[TBL] [Abstract][Full Text] [Related]
19. Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a cross-sectional case-control study from Chinese patients with HBV infection.
Gao C; Fang L; Zhao HC; Li JT; Yao SK
Hepatobiliary Pancreat Dis Int; 2013 Aug; 12(4):385-93. PubMed ID: 23924496
[TBL] [Abstract][Full Text] [Related]
20. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
